Results 141 to 150 of about 5,003 (295)
Impact of HLA antigen and antibody expression on cross-matching and transfusion effect
Zhongguo shuxue zazhi[Objective] To study the relationship between the expression intensity of HLA-Ⅰ platelet antibodies in patients with platelet transfusion refractoriness (PTR) and platelet cross-matching, and to further evaluate other factors in order to provide relevant
HE Honghong +4 more
doaj +1 more source
Platelet enumeration in dense aggregates [PDF]
arXivIdentifying and counting blood components such as red blood cells, various types of white blood cells, and platelets is a critical task for healthcare practitioners. Deep learning approaches, particularly convolutional neural networks (CNNs) using supervised learning strategies, have shown considerable success for such tasks.
arxiv
Phase 2 Multi‐Arm Study of Magrolimab Combinations in Patients With Acute Myeloid Leukaemia
eJHaem, Volume 6, Issue 3, June 2025.ABSTRACT Introduction This phase 2 study evaluated magrolimab+venetoclax (VEN)+azacitidine (AZA) in untreated, unfit acute myeloid leukaemia (AML) and magrolimab+mitoxantrone+etoposide+cytarabine in relapsed/refractory (R/R) AML. Methods Endpoints included complete remission rate (CRR), overall response rate (ORR), overall survival (OS) and safety ...
Gabriel N. Mannis +17 more
wiley +1 more source
Refining Platelet Purification Methods: Enhancing Proteomics for Clinical Applications [PDF]
arXivBackground: Platelet proteomics offers valuable insights for clinical research, yet isolating high-purity platelets remains a challenge. Current methods often lead to contamination or platelet loss, compromising data quality and reproducibility. Objectives: This study aimed to optimize a platelet isolation technique that yields high-purity samples ...
arxiv
eJHaem, Volume 6, Issue 3, June 2025.ABSTRACT Background The hypomethylating agent azacitidine (AZA) is the most widely used first‐line treatment for patients with higher‐risk myelodysplastic syndromes (MDS) due to its survival benefits. Effective management of higher‐risk MDS requires addressing not only clinical outcomes but also the burden of healthcare resource utilisation ...
Simone Juline Brommann +5 more
wiley +1 more source
Prediction model of platelet transfusion refractoriness in patients with hematological disorders
Zhongguo shuxue zazhiObjective To explore the risk factors for platelet transfusion refractoriness(PTR)in patients with hematological disorders, construct a prediction model and validate the model efficacy.
Shuhan YUE +7 more
doaj +1 more source
Rheumatology &Autoimmunity, Volume 5, Issue 2, Page 101-115, June 2025.This review seeks to provide a thorough synthesis of the existing literature on the role of thrombopoietin receptor agonists in the treatment of primary and secondary immune thrombocytopenia, with particular emphasis on the compound Hetrombopag. Abstract Immune thrombocytopenia (ITP) is a rare autoimmune disorder characterized by a platelet count below
Jiaqi Hu +8 more
wiley +1 more source
[Chinese expert consensus on the diagnosis and management of platelet transfusion refractoriness (2022)]. [PDF]
Zhonghua Xue Ye Xue Za Zhi, 2022 Chinese Society of Hematology +1 more
europepmc +1 more source
Immunological platelet transfusion refractoriness: current insights from mechanisms to therapeutics
PlateletsAlthough there have been tremendous improvements in the production and storage of platelets, platelet transfusion refractoriness (PTR) remains a serious clinical issue that may lead to various severe adverse events.
Xiaoyu Chen +3 more
doaj +1 more source